TherapeuticsMD (TXMD) EBITDA (2010 - 2026)

TherapeuticsMD has reported EBITDA for 17 years, with the latest figure at -$723000.0 in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 43.56% year-over-year to -$723000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.8 million (up 34.56% YoY), and the FY2025 full-year result was -$4.4 million, up 28.17% from the prior year.
• EBITDA for Q1 2026 stood at -$723000.0, up from -$1.6 million in the prior quarter.
• The five-year high for EBITDA was $112.3 million in Q2 2022, with the low at -$49.0 million in Q1 2022.
• Historically, EBITDA has averaged $5.3 million across 5 years, with a median of -$1.1 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA surged 363.25% — and 2025, when it slumped 138.04%.
• TherapeuticsMD's EBITDA stood at $77.7 million in 2022, then plunged by 101.14% to -$883000.0 in 2023, then rose by 26.16% to -$652000.0 in 2024, then tumbled by 138.04% to -$1.6 million in 2025, then soared by 53.41% to -$723000.0 in 2026.
• The last three EBITDA figures came in at -$723000.0 (Q1 2026), -$1.6 million (Q4 2025), and -$862000.0 (Q3 2025), per Business Quant data.